NeoPred, a dual-phase CT AI tool, accurately predicts major pathological response in NSCLC patients preoperatively.
Key Details
- 1NeoPred combines pre-treatment and pre-surgery CT scans with clinical data to predict major pathological response (MPR) in NSCLC undergoing neoadjuvant chemo-immunotherapy.
- 2Study included 509 patients across four oncology centers (459 retrospective, 50 prospective, 59 external validation).
- 3NeoPred reached AUCs of 0.772 (imaging only) and 0.787 (imaging plus clinical data) on external validation, outperforming thoracic surgeons (AUC 0.760 vs 0.720) in prospective testing.
- 4AI support improved surgeons' AUC to 0.829 and diagnostic accuracy to 82%.
- 5NeoPred identified 'pseudo-stable' responders missed by standard RECIST criteria, with AUCs of 0.742 (external) and 0.833 (prospective).
Why It Matters
Accurately predicting response before surgery could enable earlier, evidence-based clinical decisions for NSCLC, reducing overtreatment and personalizing care. This work demonstrates the expanding role and performance advantage of AI-assisted imaging over traditional assessment in complex oncologic management.
Source
EurekAlert
Related News
•EurekAlert
AI Achieves Precision in Generating Radar Images at Specific Attitudes
Researchers introduce a ControlNet-based AI method for precise, attitude-controllable radar image generation of noncooperative targets.
•EurekAlert
Novel Nanophotonic Chip Enhances Machine Vision with Quantum Wells and Metasurfaces
Researchers developed a nanophotonic processor integrating quasi-BIC metasurfaces with MQWs, demonstrating tunable photoresponse for advanced machine vision.
•EurekAlert
RADAR AI Sets New Standard in Abdominal CT Diagnosis
The RADAR vision-language AI model shows expert-level diagnostic ability for abdominal CT across multiple diseases and clinical settings.